Incyte bags more Jakafi studies in solid tumors, but maintains hope for combo success

Incyte ($INCY) pulled the plug on several Jakafi studies as the blood cancer therapy proved less effective in solid tumors when used solo. The company still sees potential in the field with Jakafi cocktails, including combos that pair the med with immuno-oncology meds. Jakafi is marketed outside the U.S. by Novartis ($NVS), which brought in $410 million from the drug last year; Incyte's U.S. sales amounted to $601 million. More from FierceBiotech